Competitive intelligence on
small-molecule drugs and
the 80,000 global patents
covering them

Start your free trial now

No commitment — No credit card required

DrugPatentWatch Archives

You are currently viewing the 2011 archives
Click here to return to the current data set

DrugPatentWatch Ultimate Plan Preview

Details for NDA: 202192

« Back to Dashboard

Summary for NDA: 202192

Tradename:
JAKAFI
Applicant:
Incyte Corp
Ingredient:
ruxolitinib phosphate
Patents:1
Suppliers: see list1

Pharmacology for NDA: 202192

Mechanism of ActionProtein Kinase Inhibitors
Glossary

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET; ORALStrengthEQ 5MG BASE
Approval Date:Nov 16, 2011TE:RLD:No
Patent:7,598,257Patent Expiration:Dec 24, 2027Product Flag?YSubstance Flag?YDelist Request?
Patented Use:FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS


Complete Access Available with Subscription
« Back to Dashboard

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc